

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **MicroPort CardioFlow Medtech Corporation**

**微创心通医疗科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2160)**

### **VOLUNTARY ANNOUNCEMENT AMENDMENTS TO SHARE AWARD SCHEME**

Reference is made to the announcement of MicroPort CardioFlow Medtech Corporation (the “**Company**”) dated March 31, 2021 (the “**Announcement**”) in relation to the adoption of the share award scheme (the “**Share Award Scheme**”). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

Under the Share Award Scheme, the Shares to be awarded to the Selected Participants could be satisfied either by (a) existing Shares purchased by the Trustee on the market at the prevailing market price (the “**Existing Shares Purchase Method**”); or (b) the new Shares issued by the Company to the Trustee under the general mandate or specific mandate granted by the shareholders of the Company (the “**New Shares Issue Method**”). The Company hereby announces that on August 29, 2023, the Board has resolved to amend the Scheme Rules to discontinue the New Shares Issue Method (the “**Amendments**”) and the amended Share Award Scheme will be satisfied only by the Existing Shares Purchase Method. Save for the Amendments, all other terms under the Share Award Scheme remain unchanged. According to the Scheme Rules and applicable Listing Rules, the Amendments do not need to be approved by the shareholders of the Company.

As no new Shares will be issued under the amended Share Award Scheme, the amended Share Award Scheme will constitute a share scheme that is funded by existing Shares as referred to under Rule 17.01(1)(b) of the Listing Rules and shall be subject to the applicable requirements under Rule 17.12 of the Listing Rules.

By order of the Board  
**MicroPort CardioFlow Medtech Corporation**  
**Chen Guoming**  
*Chairman*

Shanghai, PRC, August 29, 2023

*As at the date of this announcement, the executive directors of the Company are Mr. Jeffrey R Lindstrom, Mr. Zhao Liang and Ms. Yan Luying, the non-executive directors of the Company are Mr. Chen Guoming, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive directors of the Company are Mr. Jonathan H. Chou, Dr. Ding Jiandong and Ms. Sun Zhixiang.*